A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants

NCT ID: NCT02629744

Last Updated: 2016-11-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 27 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-12-31
• Study Completion Date: 2016-06-30

Brief Summary

This study is a multi-center, single-arm, open-label study in healthy participants to assess the pain, tolerability, injection leakage, safety, and usability of a single self-administered subcutaneous (SC) dose of etrolizumab. Some participants will receive "needle-experience" training using a needle and syringe on Days -7 and -5, and health care professionals (HCPs) will then assess the participant's suitability to self-inject with a prefilled auto-injector (AI). The remainder of participants will be "needle naïve" and will not have previously self-injected. Eligible" needle experienced" and" needle naive" participants will attend an AI training visit at the study site on Day -3 (three days prior to etrolizumab dosing on Day 1). Following training and simulated injections by the participant the HCP will determine if the participant is suitable to proceed to actual etrolizumab dosing. All eligible study participants will self administer a single dose of etrolizumab (by AI) on Day 1 and will be followed up to Day 85 following dosing. Pain, tolerability, safety and usuability will be assessed.

Conditions

Healthy Volunteer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: NONE

Study Groups

Etrolizumab

Participants will self-administer single SC dose of etrolizumab using prefilled auto-injector, into the abdomen or the anterior thigh.

Group Type: EXPERIMENTAL

Etrolizumab

Intervention Type: DRUG

Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.

Prefilled Auto-injector (Rotaject)

Intervention Type: DEVICE

Participants self-administered etrolizumabSC injection using a prefilled auto-injector.

Interventions

Etrolizumab

Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.

Intervention Type: DRUG

Prefilled Auto-injector (Rotaject)

Participants self-administered etrolizumabSC injection using a prefilled auto-injector.

Intervention Type: DEVICE

Other Intervention Names

rhuMAB Beta7

Eligibility Criteria

Inclusion Criteria

• Males or females, between 18 and 65 years of age, inclusive
• Within body mass index (BMI) range 18.0 to 32.0 kilograms per square meter (kg/m^2), inclusive
• In good health, determined by no clinically significant findings from medical history, 12-lead electrocardiograms (ECGs), and vital signs
• Females will be non-pregnant, non-lactating, and either postmenopausal (at least 1 year of non therapy induced amenorrhea), surgically sterile (absence of ovaries and/or uterus) for at least 90 days, or agree to remain abstinent or use a highly effective method of contraception for at least 24 weeks after the single dose of study drug
• Males will either be sterile or agree to remain abstinent or use a highly effective method of contraception for at least 24 weeks after the single dose of study drug. Male participants will refrain from sperm donation from Check-in (Day -1) until 24 weeks following study drug administration

Exclusion Criteria

• Participation in any other investigational study drug or biological agent trial (including investigational vaccines) in which receipt of an investigational study drug occurred within 30 days or 5 half-lives or receipt of a biologic agent occurred within 90 days or 5 half-lives, whichever is longer, prior to Check-in (Day -1) and during the entire study
• Any prior treatment with etrolizumab or other anti integrin agents (including natalizumab, vedolizumab, and efalizumab)
• Any prior exposure to immunosuppressive agents (e.g., methotrexate, azathoprine, mercaptopurine)
• Use of IV steroids within 30 days prior to Screening;
• Chronic nonsteroidal anti inflammatory drug (NSAID)
• Use of any prescription medications/products within 14 days prior to Check in (Day -1)
• History of demyelinating disease
• Neurological conditions or diseases
• History of cancer
• History of alcoholism or drug addiction within 1 year prior to Check-in (Day -1)
• History of active or latent tuberculosis (TB), regardless of treatment history
• History of recurrent opportunistic infections, severe disseminated viral infections (e.g., herpes), or any serious opportunistic infection within the last 6 months
• Positive for human immunodeficiency virus (HIV) antibody
• Any current or recent signs or symptoms of infection
• Inability to sense pain (e.g., peripheral neuropathy) and have a history of or have been diagnosed with a chronic pain syndrome

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Cypress, California, United States

Dallas, Texas, United States

Countries

United States

References

Tyrrell H, Ravanello R, Pulley J, Tang MT, Zhang W, Abouhossein M, Tole S. An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers. Adv Ther. 2021 May;38(5):2406-2417. doi: 10.1007/s12325-021-01651-8. Epub 2021 Mar 29.

Reference Type: DERIVED

PMID: 33778928 (View on PubMed)

Other Identifiers

GX29503

Identifier Type: -

Identifier Source: org_study_id